Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury

American Journal of Transplantation

Volumn 3, Issue 8, 2003, Pages 952-960

  Park, Walter D ^a   Grande, Joseph P ^a   Ninova, Dora ^a   Nath, Karl A ^a   Platt, Jeffrey L ^a   Gloor, James M ^a   Stegall, Mark D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Blood group incompatibility; Gene expression; Immunohistochemistry; Kidney transplantation; Oligonucleotide microarray

Indexed keywords

MUCIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN TYROSINE KINASE; SMAD PROTEIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CELL ADHESION; CLINICAL ARTICLE; DNA MICROARRAY; GENE EXPRESSION; GLOMERULOPATHY; GRAFT REJECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE MEDIATED INJURY; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; POSTOPERATIVE PERIOD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE;

ABO BLOOD-GROUP SYSTEM; ADAPTATION, PHYSIOLOGICAL; AUTOANTIBODIES; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CA-15-3 ANTIGEN; GENE EXPRESSION PROFILING; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0042766395     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00179.x     Document Type: Article

References (42)

1. U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network. Annual Report: Transplant Data: 1990-99. Rockville, MD, Richmond, VA. U.S: Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation, United Network for Organ Sharing; 2000.
2. Tanabe K, Takahashi K, Sonda K et al. Long-term results of ABO-incompatible living kidney transplantation. Transplantation 1998; 65:224-228.
3. Alkhunaizi AH, De Mattos AM, Barry JM, Bennett WM, Norman DJ. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999; 67: 1319-1324.
4. Bier M, Beavers CD, Merriman GW, Merkel FK, Eiseman B, Starzl TZ. Selective plasmapheresis in dogs for delay of heterograft response. Trans Am Soc Artif Intern Organs 1970; 16: 325-333.
5. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000; 70: 1331-1335.
6. Aikawa A, Hadano T, Ohara T et al. Donor specific antibody suppression in ABO-incompatible kidney transplantation. Transplant Proc 2001; 33: 395-397.
7. Chopek MW, Simmons RL, Platt JL. ABO-incompatible kidney transplantation: initial immunopathologic evaluation. Transplant Proc 1987; 19: 4553-4557.
8. Rydberg L, Breimer ME, Brynger H, Samuelsson BE. ABO-incompatible kidney transplantation (A2 to O). Qualitative and semiquantitative studies of the humoral immune response against different blood group A antigens. Transplantation 1990; 49: 954-960.
9. Vengelen-Tyler V. Technical Manual 1999. Bethesda: American Association of Blood Banks; 1999.
10. Wilson DM, Bergert JH, Larson TS, Liedtke RR. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 1997; 30: 646-652.
11. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification for renal allograft pathology. Kidney Int 1999; 55: 713-723.
12. Stegall MD, Park WD, Kim DY, Kremers WK. Gene expression during acute allograft rejection. novel statistical analysis of microarray data. Am J Transplant 2002; 2: 913-925.
13. Stegall MD, Park WD, Kim DY, Covarrubias M, KhairA, Kremers WK. Changes in intragraft gene expression secondary to ischemia-reperfusion after cardiac transplantation. Transplantation 2002; 74: 924-930.
14. Platt JL, Vercellotti GM, Dalmasso AP et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11: 450-456.
15. Salama AD, Delikouras A, Pusey CD et al. Transplant accommodation in highly sensitized patients. a potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260-269.
16. Ishida H, Koyama I, Sawada T et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations. survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000; 98: 681-685.
17. Kerman RH, Susskind B, Kerman DH et al. Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection. Transplant Proc 1997; 29: 1515-1516.
18. Plissonnier D, Henaff M, Poncet P et al. Involvement of antibody-dependent apoptosis in graft rejection. Transplantation 2000; 69: 2601-2608.
19. Bach FH, Ferran C, Hechenleitner P et al. Accommodation of vascularized xenografts: expression of 'protective genes' by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997; 3: 196-204.
20. Miyatake T, Koyamada N, Hancock WW, Soares MP, Bach FH. Survival of accommodated cardiac xenografts upon retransplantation into cyclosporine-treated recipients. Transplantation 1998; 65: 1563-1569.
21. Lin Y, Soares MP, Sato K et al. Accommodated xenografts survive in the presence of anti-donor antibodies and complement that precipitate rejection of naive xenografts. J Immunol 1998; 163: 2850-2857.
22. Platt J, Nath K. Heme oxygenase: protective gene or Trojan horse. Nat Med 1998; 4: 1364-1365.
23. Massagué J, Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J 2000; 19: 1745-1754.
24. Lo RS, Wotton D, Massagué J. Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO J 2001; 20: 128-136.
25. Zhou S, Buckhaults P, Zawel L et al. Targeting deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci 1998; 95: 2412-2416.
26. Robertson K, Mason I. The GDNF-RET signalling partnership. Trends Genet 1997; 13: 1-3.
27. Cummings DE, Brandon EP, Planas JV, Motamed K, Idzerda RL, McKnight GS. Genetically lean mice result from targeted disruption of the RIIβ subunit of protein kinase A. Nature 1996; 382: 622-626.
28. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897-901.
29. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11: 372-377.
30. Barnes PJ, Karin M. Mechanisms of disease: nuclear factor-kB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
31. Deng L, Wang C, Spencer E et al. Activation of the I-kappa-B complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-361.
32. Leroy X, Copin MC, Devisme L et al. Expression of human mucin genes in normal kidney and renal cell carcinoma. Histopathology 2002; 40: 450-457.
33. McDermott KM, Crocker PR, Harris A et al. Overexpression of MUC1 reconfigures the binding properties of tumor cells. Int J Cancer 2001; 94: 783-791.
34. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993; 151: 767-776.
35. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001; 276: 13057-13064.
36. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998; 4: 43-49.
37. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995; 55: 4000-4003.
38. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996; 56: 4244-4249.
39. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6: 339-353.
40. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134: 1033-1042.
41. Savage CO, Harper L, Holland M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2002; 14: 15-22.
42. Pietropaolo M, Eisenbarth GS. Autoantibodies in human diabetes. Curr Dir Autoimmun 2001; 4: 252-282.